Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524824 | NSE Symbol : BALPHARMA | ISIN : INE083D01012 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
24-Jan-2025	13-Feb-2025	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve Unaudited standalone and consolidated financial results for the quarter ended 31.12.2024 and to consider fund raising options . Board of Directors at their meeting held on 13.02.2024 has inter alia , 1.Taken on record and approved Unaudited stand alone and consolidated financial results for the quarter and 9 months ended 31.12.2024. 2. Differed to consider fund raising options due to unfavorable and volatile market conditions. Additional details for Corporate Announcement filed under Regulation 30 of SEBI(LODR)Regulations,2015, dated 13.02.2025. (As per BSE Announcement Dated on 13/02/2025)
05-Nov-2024	14-Nov-2024	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Un-audited standalone and consolidated financial results of the company for the quarter and half year ended 30.09.2024 Board of Directors at their meeting held on 14.11.2024 has inter alia taken on record and approved the Un-audited financial results of the Company for the quarter and half year ended 30.09.2024. (As Per BSE Announcement Dated on: 14/11/2024)
30-Aug-2024	09-Sep-2024	Employee Stock Option	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/09/2024 inter alia to consider and approve 1. Allotment of equity shares to the employees of the Company upon conversion of stock options vested on them. 2. To consider expanding its manufacturing presence to meet growing demand for APIs. 3.Any other matters incidental to the business operations and ensuing AGM of the Company. Outcome of the Board Meeting- Announcement under Regulation 30 of SEBI(LODR) Regulations. (As Per BSE Announcement Dated on 09.09.2024) Further to our intimation to the exchanges reg the Outcome of Board meeting dated 09.09.2024, we would like to clarify that the actual cost of the project that is being undertaken at Kadechur KIADB Industrial area, Yadgir Distriact, Karnataka is estimated to be around Rs.40 Crores and not Rs.30 Crores as stated in our above mentioned intimation inadvertently. Request you to please take this intimation on record. Read less.. (As Per BSE Announcement Dated on 11.09.2024)
26-Jul-2024	12-Aug-2024	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve 1. Un-Audited financial Results for the quarter ended 30.06.2024. 2.To review the requests of the promoters for reclassification. 3. To convene 37th Annual General Meeting of the Company. 4. To Decide on Book Closure dates. 5. Other AGM related matters. 6. Allotment of equity shares to the employees of the Company upon conversion of stock options. Inter alia 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2024. 2. Convened 37th Annual General Meeting of the Company on 25th September 2024. 3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2024 to 25.09.2024(both days inclusive ) to ascertain the entitlement of Dividend and for 37th AGM. 4.Approved the re-classification of promoter share holding subject to the approval of shareholders. As per Regulation 31 A (8)(b) of LODR Regulations, we are circulation the extract of the minutes of BOD held on 12.08.2024 pertaining to reclassification of promoters. (As Per BSE Announcement Dated on 03.12.2024)
30-Apr-2024	28-May-2024	Accounts	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve 1.Audited Standalone and Consolidated financial results for the quarter and financial year ended 31.03.2024. 2.Audited standalone and consolidated accounts of the Company together with Directors and Auditors reports. 3. Recommendation of Dividend if any for the financial year ended 31.03.2024. 4.Appoinment of Internal Auditors Cost Auditors and Secretarial Auditors for f.y ended 31.03.2024. Board of Directors of the Company has met today and inter alia transacted the following business, 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM. 2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25. (As Per BSE Announcement Dated on: 28/05/2024)
25-Jan-2024	12-Feb-2024	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve 1) Un-Audited Standalone and Consolidated financial results of the Company for the quarter and nine months ended 31.12.2023. 2)To consider investing additional capital in expanding its manufacturing presence through a green field project. 1. Taken on record and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and 9 Months ended 31.12.2023. A copy of the approved financial results together with Limited Review Reports issued by the statutory auditors of the company with unmodified opinion is enclosed with this intimation. 2. The Board has considered and acknowledged the receipt of letter of allotment from KIADB allotting 5 acres of land to the company at Kadechur KIADB industrial area, Yadgiri, Karnataka. The proposed project for setting up of the API and Intermediaries manufacturing facility at the above said industrial are was approved at the State Level Single Window Clearance Committee, Government of Karnataka. (As per BSE Announcement Dated on 12/02/2024)
20-Oct-2023	08-Nov-2023	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve 1. Unaudited financial results for the quarter and half year ended 30.09.2023. 2.Allotment of equity shares to the employees of the Company who has exercised the conversion option on employee stock options vested on them. 3. To grant stock options under Bal Pharma Ltd-Employee stock option scheme 2014 to the eligible employees of the Company. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Un-audited standalone and consolidated financial results of the Company for the quarter and half year ended 30.09.2023. A copy of the approved financial results together with the limited review report issued by the statutory auditors of the Company with unmodified opinion is enclosed with this intimation. 2. Approved the allotment of 1,18,500 Equity shares to the employees of the Company who has exercised the employee stock options vested on them. 3. Approved the grant of 1,83,500 stock options to the eligible employees of the Company from 'Bal Pharma Ltd-Employee stock option plan-2014'. The meeting of the Board has commenced at 4.45 p.m. and concluded at 5.40 p.m on Wednesday, 8th November 2023. The Board of Directors of the Company has inter alia taken on record and approved the unaudited financial result of the Company for the quarter and half year ended 30.09.2023 (As Per BSE Announcement Dated on 08/11/2023)
01-Aug-2023	11-Aug-2023	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve 1.Un-Audited Standalone and Consolidated financial results of the Company for the quarter ended 30.06.2023. 2.To convene the 36th Annual General Meeting of the Company. 3. To decide on the Book closure dates. 4. Other AGM related matters. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Un-audited standalone and consolidated financial results of the Company for the quarter ended 30.06.2023. A copy of the approved financial results together with the limited review report issued by the statutory auditors of the Company with unmodified opinion is enclosed with this intimation. 2. Decided to convene 36th Annual General Meeting of the Company on 25th September 2023 i.e on Monday at 10:30 A.M, through audio visual means. 3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2023 to 25.09.2023 (both days inclusive) to ascertain the entitlement of Dividend and for the 36th Annual General Meeting of the Company. The meeting commenced at 4.30 p.m. and concluded at 5:40 p.m on Friday, 11th August 2023. (As Per BSE Announcement Dated on 11.08.2023)
16-May-2023	29-May-2023	Accounts	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve 1.audited standalone and consolidated financial results for the quarter and financial year ended 31.03.2023. 2.audited Standalone and Consolidated accounts of the Company together with Directors and Auditors reports for F.Y ended 31.03.2023. 3. recommendation of dividend if any for the financial year ended 31.03.2023. 4. appointment of Internal Auditors Cost Auditors and Secretarial Auditors for F.Y 2023-24. The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31.03.2023. A copy of the Audited financial statements (Standalone and Consolidated) along with auditors reports with unmodified opinion are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Appointed Mr.M.R Krishna Murthy (Membership No. 7568) as Cost Auditor , Mr.Parameshwar Bhat (Membership No.8860) as Secretarial Auditors and Messrs. Murugesh & Co ( Membership No.002233S) as internal auditors of the Company for the financial year 2023-2024. The meeting commenced at 4.45 P.M and concluded at 6.20 P.M on 29.05.2023. (As Per BSE Announcement Dated on 29.05.2023)
27-Jan-2023	06-Feb-2023	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2023 inter alia to consider and approve Unaudited financial results of the Company for the quarter ended 31.12.2022. Further pursuant to amended provisions of SEBI (Prohibition of Insider Trading Regulations)2015 and as per the provisions of Code of Conduct of the Company the trading window for dealing in securities of the Company by its designated persons/employees and their immediate relatives was closed from 01.01.2023 up to 08.02.2023 i.e 48 hours after declaration of financial results of the Company. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022. A copy of the standalone and consolidated financial results together with the limited review reports issued by the statutory auditors of the Company with un modified opinion, is enclosed. 2.Appointed Mr.Bharath Bhushan D.V as Chief Financial Officer of the Company w.e.f 06.02.2023. A brief on the candidature of Mr.Bhartha Bhushan is enclosed as Annexure to this letter. The Board meeting commenced at 4.30 p.m and concluded at 6.20 p.m on 06.02.2023. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022. A copy of the standalone and consolidated financial results together with the limited review reports issued by the statutory auditors of the Company with un modified opinion, is enclosed. The Board meeting commenced at 4.30 p.m and concluded at 6.20 p.m on 06.02.2023. (As Per BSE Announcement Dated on 06.02.2023) Sub : Revised Consolidated Financial Results. Ref: Regulation 30 of SEBI(LODR) Regulations, 2015. With reference to the above, In continuation of our submissions to the exchange on 06.02.2023 with respect to unaudited stand alone and consolidated financial results of the Company for the quarter ended 31.12.2022, we are now submitting to the exchanges revised consolidated financial results of the Company for the quarter and nine months ended 31.12.2022. In the consolidated financial results submitted on 06.02.2023, figures for the 6 months ended 30.09.2022 was furnished as corresponding figures for previous quarter instead of furnishing figures for nine months ended 31.12.2021 as corresponding figures for previous year. We request you to take the revised consolidated financial results on record. (As Per BSE Announcement Dated on 14.02.2023)
04-Nov-2022	14-Nov-2022	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve 1.Un-audited standalone and consolidated financial results for the quarter & half year ended 30.09.2022. 2.To allot equity shares to the eligible employees upon exercise of ESOPs. 3. To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd a wholly owned subsidiary of the Company. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed . 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company. 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022. (As Per BSE Announcement Dated on 14.11.2022)
29-Jul-2022	11-Aug-2022	Quarterly Results	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2022 inter alia to consider and approve Unaudited financial results for the quarter ended 30.06.2022. Board of Directors of the Company has inter alia taken on record and approved the un-audited financial results ( stand alone & consolidated ) of the Company for the quarter ended 30.06.2022. (As Per BSE Announcement Dated 11.08.2022)
12-May-2022	30-May-2022	Final Dividend	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve 1.Audited financial results for the quarter and year ended 31.03.2022. 2.Recommendation of Dividend if any for the F.Y 2021.22 3.To decide on the Book closure dates. 4. To convene the 35th Annual General Meeting of the Company. 5. Other AGM related matters. The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2022. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. The Board of Directors of the Company has met today and inter alia transacted the following business. 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2022. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges. 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. 3.Approved to redraft the Memorandum and Articles of Association of the Company as per the provisions of Companies Act,2013, subject to the approval of members at the ensuing Annual General Meeting. 4. Appointed Mr.Kotian Chittananda Damodar ( DIN # 09613054 ) as Additional Director ( Non Independent ) of the Company. The meeting commenced at 4.30 p.m and concluded at 6.00 p.m on 30.05.2022. (As Per BSE Announcement Dated on 30.05.2022)
05-Apr-2022	13-Apr-2022	Conversion	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/04/2022 inter alia to consider and approve allotment of equity shares to the beneficiaries who have exercised the conversion option on the warrants allotted to them on preferential basis. Pursuant to applicable provisions of Chapter V of SEBI (ICDR) Regulations, 2018 and Section 42 of the Companies Act,2013 & Companies (Prospectus and allotment of Securities) Rules, 2014 as amended from time to time and after having received the full consideration amount , the Board of Directors of the Company at its meeting held on today i.e 13.04.2022 has inter alia approved the allotment of 7,50,000 equity shares of Rs.10/- each to the following investor , upon conversion of Warrants allotted to him on preferential basis: Sl No Name of the Investor Category of Investor No of equity shares allotted Distinctive Numbers 01 Mr Shailesh Siroya Promoter 7,50,000 14822373 to 15572372 With this allotment, the paid-up equity share capital of the Company has risen to Rs.15,57,23,720/- divided into 1,55,72,372 equity shares of Rs.10 each (As Per BSE Announcement Dated on 13.04.2022)
28-Feb-2022	09-Mar-2022	Scheme of Amalgamation	BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2022 inter alia to consider and approve The meeting of Board of Directors of the Company is scheduled to be held on 9.03.2022 i.e on Wednesday to inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd subject to the approval of applicable statutes and shareholders of the Company. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its meeting held on 9th March, 2022, has considered and approved the Scheme of Merger (the 'Scheme') pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, if any, providing for the merger of its wholly owned subsidiary- Golden Drugs Private Limited ('Transferor Company') with Bal Pharma Limited ('Transferee Company'). The Scheme would be implemented subject to the requisite statutory / regulatory approvals including the approval of the National Company Law Tribunal (Bengaluru Bench). The Company will be filing joint application with Hon'ble National Company Law Tribunal (Bengaluru Bench) in due course of time to obtain approval on the scheme as required under the provisions of the Companies Act, 2013. (As Per BSE Announcement dated on 09.03.2022)

1 2

LOGIN HERE

Bal Pharma Ltd

Board Meeting